PC
URGN icon

PA Capital’s UroGen Pharma URGN Stock Holding History

PA Capital’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10,771
Closed -$192K – 198
2020
Q1 		$192K Sell
10,771
-2,717
-20% -$73.4K 0.17% 142
2019
Q4 		$450K Sell
13,488
-6,282
-32% -$171K 0.4% 90
2019
Q3 		$471K Buy
+19,770
New +$646K 0.46% 85
2019
Q2 		– Sell
-8,919
Closed -$329K – 118
2019
Q1 		$329K Buy
+8,919
New +$374K 0.29% 86

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HCM
Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return

PA Capital's URGN Position: Q2 2020 in Review

PA Capital sold out of UroGen Pharma (URGN) in Q2 2020, closing a stake of 10,771 shares — an estimated $192K sold.

PA Capital first reported a position in URGN in Q1 2019 and held it in 4 quarters. The position peaked at $471K in Q3 2019. 84 funds tracked by Wall St. Rank hold URGN as of Q2 2020.

  • PA Capital reported no remaining UroGen Pharma position as of Q2 2020 after selling out during the quarter.
  • PA Capital sold 10,771 UroGen Pharma shares in Q2 2020, an estimated $192K.
  • PA Capital first reported a position in UroGen Pharma in Q1 2019 and held it in 4 quarters.
  • PA Capital's UroGen Pharma position peaked at $471K in Q3 2019.
  • 84 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2020.

Based on PA Capital's 13F filing for Q2 2020, filed 13 Aug 2020.